A Phase 1, Open-Label, Randomized, Single-Dose, Parallel Design, Study to Evaluate Pharmacokinetic Comparability of Two PF-07940367 Film-Coated Tablet Formulations Administered as 150 mg Under Fasted Conditions in Healthy Participants

Nov 3, 2026

A Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Dystrophin Expression After Fordadistrogene Movaparvovec (PF-06939926) Administration in Male Participants With Early Stage Duchenne Muscular Dystrophy

Oct 30, 2026